Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2022 Earnings Conference Call March 8, 2023 8:30 AM ET

Company Participants

Allison Wey - Senior Vice President, Investor Relations, and Corporate Communications

Paul Edick - Chairman and Chief Executive Officer

Steve Pieper - Chief Financial Officer

Conference Call Participants

Oren Livnat - H.C. Wainwright

Roanna Ruiz - SVB Securities

David Amsellem - Piper Sandler

Operator

Hello and welcome to the Xeris Biopharma Fourth Quarter and Year-End 2022 Conference Call. My name is Alex, and I will be coordinating the call today. [Operator Instructions]

I will now hand over to your host Allison Wey, Senior Vice President of Investor Relations and Corporate Communications. Please go ahead.

Allison Wey

Thank you, Alex. Good morning and welcome to Xeris’ fourth quarter and full-year 2022 financial results conference call and webcast. A press release with the company’s financial results was issued earlier this morning and can be found on our website. We are joined this morning by Paul Edick, Chairman and CEO; and Steve Pieper, CFO. Paul will provide opening remarks, Steve will provide details on our financial results, and after a few closing remarks by Paul we will open the call for Q&A.

Before we begin, I would like to remind you that this call will contain forward-looking statements which may include but are not limited to statements concerning our business practices, future expectations, plans, prospects, clinical approvals, commercialization, corporate strategy, and performance which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Actual results may differ materially from those indicated by these forward-looking statements made during this call, as a result of various important factors, including our financial position and need for financing including to fund our product development programs or commercialization efforts.

Whether our products will achieve and maintain market acceptance, our reliance on third party suppliers, including single source suppliers, our reliance on third parties to conduct clinical trials, the ability of our product candidates to complete successfully with existing and new drugs.

The effect of uncertainty is related to the impact COVID-19 on our business operations and clinical activities and our collaborators' ability to protect our intellectual property and proprietary technology, as well as other risk factors set forth in our filings with the Securities and Exchange Commission. Any forward looking statements in this call represent our views only as of the date of this call and should not be relied upon as representing our views as of any subsequent date. Subject to obligations under applicable law, we disclaim any obligations to update such statements.